[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:high-grade-b-cell-lymphoma:mbd5-wt-allele":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"High Grade B-Cell Lymphoma","MBD5 wt Allele",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07316010","Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:19:27.519777Z","2026-05-05T02:35:31.631978Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06500273","Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",[12],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.207810Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[26],"Phase 1","2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z"]